Early-stage returns?

Nature Biotechnology

Volumn 24, Issue 11, 2006, Pages 1335-1340

  Booth, Bruce L ^a  

^a 400 Technology Square   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTOXIN; ROFECOXIB;

BIOTECHNOLOGY; CAPITAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GENOMICS; HIGH THROUGHPUT SCREENING; INVESTMENT; MEDICAL LITERATURE; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; SCIENCE;

BIOTECHNOLOGY; CAPITAL FINANCING; DRUG INDUSTRY; ECONOMIC COMPETITION; INVESTMENTS; UNITED STATES;

EID: 33750850904     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1106-1335     Document Type: Note

References (8)

1. Bernstein, K. Venture capital changes its model. BioCentury December 5, 2, A1-A4 (1994).
2. Bernstein, K. Funding models. BioCentury December 7, 6, A1-A5 (1998).
3. MacArthur, R. Ecology 35, 533-536 (1955).
4. Booth, B. & Zemmel, R. Nat. Rev. Drug Disc. 3, 451-456 (2004).
5. Association of University Technology Managers (AUTM). Licensing Survey 2004 (AUTM, Northbrook, Illinois, 2004).
6. Booth, B. Nat. Rev. Drug Disc. 4, 533-534 (2005).
7. Herskovits, B. PharmaExec Direct August 16 (2006).
8. National Venture Capital Association. 2006 Venture Capital Yearbook (NVCA, Arlington, Virginia, 2006).